MARINA KURMAN: Open Payments
NPI 1871655977 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,796 in 86 payments from 17 companies in 2025. Trend: 2023 $3,361 · 2024 $3,058 · 2025 $1,796
Food & beverage: $1,796
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 18 | $403 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $189 |
| ABBVIE INC. | 9 | $183 |
| Amgen Inc. | 8 | $167 |
| Sumitomo Pharma America, Inc. | 11 | $160 |
| Axsome Therapeutics, Inc. | 7 | $148 |
| Incyte Corporation | 5 | $130 |
| Medtronic, Inc. | 3 | $94 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $88 |
| Novo Nordisk Inc | 2 | $55 |
Products named: BREZTRI, XIFAXAN, GEMTESA, Symbravo, FARXIGA, OPZELURA, OTEZLA, QULIPTA.
Industry payments across NY — which companies pay providers there.
